Michael Okunewitch
Stock Analyst at Maxim Group
(0.53)
# 4,173
Out of 5,115 analysts
30
Total ratings
23.08%
Success rate
-16.53%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.29 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.21 | +726.45% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.06 | +466.04% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $1.05 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $1.11 | +3,053.15% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $5.05 | +137.62% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.55 | +1,706.45% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.19 | +1,076.47% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.48 | +102.70% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.45 | +175.86% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.33 | +3,516.64% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.56 | +972.00% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.78 | +1,431.20% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.79 | +1,240.78% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.40 | +650.00% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.15 | +94,086.05% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.13 | +37.89% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.14 | +426.32% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.76 | +564.89% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.74 | +13,411.69% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.29
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.21
Upside: +726.45%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.06
Upside: +466.04%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.05
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $1.11
Upside: +3,053.15%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $5.05
Upside: +137.62%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.55
Upside: +1,706.45%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.19
Upside: +1,076.47%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.48
Upside: +102.70%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.45
Upside: +175.86%
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.33
Upside: +3,516.64%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.56
Upside: +972.00%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.78
Upside: +1,431.20%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.79
Upside: +1,240.78%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.40
Upside: +650.00%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.15
Upside: +94,086.05%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.13
Upside: +37.89%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.14
Upside: +426.32%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.76
Upside: +564.89%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.74
Upside: +13,411.69%